Recent News

• 05.01.2025 - Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
• 11.26.2024 - Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
• 11.07.2024 - Dihydroergotamine for migraine: Evidence for multiple modes of action: The single molecule ‘combination’ product—A narrative review
• 10.31.2024 - Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
• 10.08.2024 - Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
• 10.08.2024 - Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study
• 06.13.2024 - Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label ASCEND Study
• 06.13.2024 - Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label ASCEND Study
• 06.13.2024 - Subjects View Use of STS101 Favorably: Subject Impression Data From the Phase 3 Open-Label ASCEND Study
• 06.13.2024 - STS101 (Dihydroergotamine Nasal Powder) Shows Pain Relief in Difficult to Treat Migraine Attacks: Results From the Phase 3 Double-blind, Randomized, Placebo-controlled SUMMIT Study

Recent Filings